The Executive Board is an elected group of active members in AIA who are divided amongst the following positions: Chief Executive Officers, Chief Operating Officers, Chief Communication Officers, and Chief Technical Officer. These positions are reset every first general meeting of the academic year (August), with nominated individuals elected for respective positions.
Ian Shelton (he/him) My current work in Craig Jordan’s lab is focused on characterizing the heterogeneity of leukemia stem cells (LSCs) in acute myeloid leukemia (AML) patients. Specifically, my interest is to dissect intra-patient AML heterogeneity, which is the main driver of therapeutic relapse. Through deeper understanding of LSC heterogeneity at the genetic, epigenetic, metabolic and developmental levels, we can lay the groundwork for precision medicine designed to eliminate relapse responses in AML patients with evident LSC heterogeneity.
In addition to bench-based functional studies, I’m also interested in leveraging multi-omic and single cell bioinformatic techniques to address disease heterogeneity. Combining powerful bioinformatic approaches with in vitro and in vivo functional studies on the bench will provide unprecedented resolution of the biological mechanisms driving leukemogenesis in patients and therapeutic resistance in the clinic.
Outside of the lab, I’m quite active in many of the outdoor activities Colorado has to offer – I’ve climbed 32/58 Fourteeners, I enjoy running marathons, backcountry skiing, cycling, climbing, and fishing.
Lily Elizabeth Feldman (she/her) I am a Pharmacology PhD student in the Costello Lab, where my work focuses on characterizing mechanisms of treatment resistance in human muscle-invasive bladder cancer (MIBC). Our lab specializes in cancer systems biology, where we integrate multi-omics bioinformatics with molecular biology to better understand chemoresistance in solid tumor cancers. Our goal is to use large, publicly available datasets to learn about treatment effectiveness in MIBC patients, then follow these leads into the lab where we work to develop therapeutic interventions to improve patient outcomes.
I received my B.S. in Biochemistry from the University of New Mexico in 2020, where I completed a senior thesis on the effects of intermittent fasting on adipose tissue remodeling and fat loss. I also earned a minor in Chinese and learned how to culture cells in Mandarin.
When I'm not lab, I love to spend time in the mountains - hiking, climbing, or skiing as the seasons allow. I am a certified Emergency Medical Technician (EMT) and have previously worked as a ski patroller, rock-climbing teaching assistant, and ambulance driver.
Bridget Hoag (she/her) is Co-COO of the Academia Industry Alliance. Bridget is pursuing her PhD in Cancer Biology at the University of Colorado Anschutz. She researches the evolution of splicing mutations in clonal hematopoiesis and acute myeloid leukemia in the lab of Dr. James DeGregori. Bridget grew up right here in Colorado and received her BS in biochemistry from Gonzaga University. Prior to starting her PhD, she worked as a research associate at Genentech in South San Francisco, in the department of Biochemistry and Cellular Pharmacology. Outside of work, you can find Bridget skiing, hiking, camping, or backpacking!
Jillian Ramos (she/her) is Co-COO of the Academia Industry Alliance. She is a Postdoctoral Scholar in Dr. Jeffrey Kieft's lab in the Department of Biochemistry and Molecular Genetics at the University of Colorado Anschutz Medical Campus. Her postdoctoral work involves developing a new RNA-based technology in hopes to be used as a future therapeutic. Outside of lab she is classified as an Elite-level Powerlifter holding multiple state records and a national record.
Alana Keller (she/her) is a Co-CCO of the Academia Industry Alliance. Alana is a Cancer Biology PhD student researching immunotherapies for multiple myeloma in the lab of Dr. Daniel Sherbenou. She received her BS in chemistry at the University of North Carolina- Chapel Hill (go Tar Heels!) and worked as a technician at UNC-Chapel Hill’s HIV Cure Center before moving to Colorado. Upon graduation, she plans to follow her interests in immuno-oncology within the realm of industry.
Regan Miller (she/her) is Co-CCO of the Academia Industry Alliance. She is working towards her PhD in the Cancer Biology Program at the University of Colorado Anschutz Medical Campus. She is currently a 2nd year graduate student in the Jordan Lab in the Division of Hematology. During her graduate studies, she hopes to translate her findings at the bench to improve the clinical outcomes of patients with acute myeloid leukemia (AML). Before coming to CU-AMC, Regan had gotten her B.S. and M.S. in Biology from Oakland University in Rochester, Michigan. When Regan is not in the lab, she is hiking, watching documentaries, or tending to her many houseplants.
Lisa Wood (she/her) is the CFO of the Academia Industry Alliance. Lisa is a Cancer Biology PhD student researching mechanisms of chemoresistance. She is in the Moore lab in the Department of Cell and Developmental Biology. Her research focuses on how protein of the cytoskeleton have evolved to have specific functions and how certain cancers might hijack these unique functions. Lisa received her B.S in Molecular Genetics from the University of Vermont. She hopes to go into industry after graduating where she can work on drug discovery and researching new compounds. When she is not in the lab she enjoys hiking, biking, CrossFit, and playing with her dog.
Michael Orman (he/him) is CTO of the Academia Industry Alliance. Michael is a third-year doctoral candidate in the Pharmacology program at the University of Colorado Anschutz Medical Campus. He is working in the Costello lab, where he is interested in understanding how an aggressive subtype of prostate cancer (PCa) progresses to metastatic disease. To investigate this question, Michael utilizes a combination of bioinformatics tools and wet lab techniques to probe molecular factors that may contribute to PCa progression. Ultimately, the goal of his work is to discover clinically-relevant regulators of PCa aggressiveness. In his spare time, Michael enjoys being outdoors, cooking, and spending time with his friends and family.
Bruce Mandt, Ph.D. (he/him) is an Assistant Dean in the Graduate School and Director of the Postdoctoral Office and the Career Development Office at the University of Colorado Denver|Anschutz Medical Campus (CU Denver/Anschutz). Bruce’s primary function is to ensure that CU Denver/Anschutz provides a supportive and effective training environment where graduate students and postdoctoral fellows can acquire the professional skills and experiences requisite for successful career transitions. Bruce believes that participation with trainee organizations, like AIA, is critical for trainees to test drive different career interests, gain valuable career skills and experiences, and expand their professional networks.